The estimated Net Worth of Eric Sandberg is at least $1.3 Milione dollars as of 16 March 2022. Mr. Sandberg owns over 6,000 units of Axogen stock worth over $190,037 and over the last 6 years he sold AXGN stock worth over $0. In addition, he makes $1,113,440 as Chief Commercial Officer at Axogen.
Eric has made over 1 trades of the Axogen stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of AXGN stock worth $79,680 on 16 March 2022.
The largest trade he's ever made was exercising 6,000 units of Axogen stock on 16 March 2022 worth over $79,680. On average, Eric trades about 667 units every 0 days since 2019. As of 16 March 2022 he still owns at least 14,310 units of Axogen stock.
You can see the complete history of Mr. Sandberg stock trades at the bottom of the page.
Eric A. Sandberg serves as Chief Commercial Officer of the Company. Mr. Sandberg has served as Axogen’s Chief Commercial Officer since January 2019. From 2016 until joining Axogen, he served as the Chief Executive Officer of Visura Technologies, Inc., a cardiologist-founded medical device company. From 2016 until 2018, Mr. Sandberg served as the Chief Business Officer of Rhythm Therapeutics, Inc., an electrophysiologist-founded preclinical biotechnology company. From 2014 until 2016, he served as the President and Chief Executive Officer of Tangent Medical Technologies, Inc., a medical device company. Mr. Sandberg also served as Senior Vice President, Sales at CardioDx, Inc., a molecular diagnostics company, from 2008 until 2013. Prior to joining CardioDx, Inc., Mr. Sandberg worked at Russell Reynolds Associates and held leadership positions across sales, marketing, corporate accounts, and business development at Guidant Corporation and Boston Scientific. Mr. Sandberg currently serves as an observer on the Board of Directors of Visura Technologies, Inc. Mr. Sandberg earned an MBA from Harvard Business School and a Bachelor of Science degree in mechanical engineering from Bradley University in Peoria, IL.
As the Chief Commercial Officer of Axogen, the total compensation of Eric Sandberg at Axogen is $1,113,440. There are no executives at Axogen getting paid more.
Eric Sandberg is 55, he's been the Chief Commercial Officer of Axogen since 2019. There are 10 older and 4 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
Eric's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels e Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: